6 results about "Anorectic" patented technology

Methods of treating one or more eating disorders including anorexia nervosa, bulimia, and related clinical syndromes in a subject in need thereof are described. In some cases, electric stimulation and / or one or more active agents are administered to a subject in need thereof to reduce or inhibit the activity of CeA PKC-δ neurons and ovBNST PKC-δ neurons in the brain of the subject. Preferably, the disclosed methods are effective to increase or excite the activity of the brain regions downstream of CeA PKC-δ neurons and ovBNST PKC-δ neurons including medial part of CeA and ventral lateral part of BNST.

The invention concerns methods for treating unwanted body weight loss, and / or medically undesired body weight loss, or eating disorders (such as anorexia nervosa), by administration of a leptin receptor agonist, such as metreleptin. The invention also relates to methods for increasing body weight in a subject in need of the treatment.

The present invention relates to a pharmaceutical composition for preventing, ameliorating, or treating anorexia and weight loss, comprising a Bupleuri Radix extract. Specifically, the present invention provides a pharmaceutical composition having effects in preventing, ameliorating, or treating anorexia and weight loss, wherein a Bupleuri Radix extract increases ghrilin, which is a hormone that stimulates appetite, and decreases TPH1(I), which is a serotonin synthase. In addition, a health functional food for preventing or ameliorating anorexia and weight loss, comprising a Bupleuri Radix extract, can be developed, and the extract can be effectively used for the treatment and the development of therapeutic agents for anorexia induced by chemotherapy in the future.

Pharmaceutical compositions comprising a neuropeptide B / W receptor (NPBWR1) antagonist / inhibitor are described for use in methods of treating, ameliorating or preventing mood disorders / affective disorders and / or chronic stress and / or anxiety disorders and / or Parkinson's disease. Furthermore, pharmaceutical compositions comprising a neuropeptide B / W receptor (NPBWR1) agonist / activator are described for use in methods of treating, ameliorating or preventing bipolar disorder manic (ICD-10 F31), appetite disorders, preferably anorexia or bulimia. Furthermore, a method of assessing the activity of a candidate molecule suspected to be a NPBWR1 antagonist / inhibitor or agonist / activator is described.

Use of sesquiterpenoids having the structures of formula (I) and formula (П) in relieving nausea and vomiting. The sesquiterpenoids having the structures of formula (I) and formula (П) are cedrol and analogs, racemates, stereoisomers, tautomers, isotopically labeled compounds, solvates, polymorphs, metabolites, prodrugs, or pharmaceutically acceptable salts thereof, wherein R 1 to R 8 are as described in the claims and the description. The compounds having the structures of formula (I) and formula (П) can reduce kaolin intake in pica rats, significantly alleviate the symptoms of nausea and vomiting induced by chemotherapeutic drugs such as cisplatin when used in tumor treatment, and can also relieve vomiting caused by gastrointestinal injury, inflammatory diseases, anorexia, etc. In addition, the compounds having the structures of formula (I) and formula (П) can also be used in the preparation of drugs for relieving / treating nausea and vomiting or in the preparation of foods for assisting in protecting the gastric mucosa.